We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
-5.01%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$7.91B
AUM Growth
-$1.41B
(-15%)
Cap. Flow
-$1B
Cap. Flow
% of AUM
-12.68%
Top 10 Holdings %
Top 10 Hldgs %
40.65%
Holding
174
New
35
Increased
19
Reduced
37
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LABP
Landos Biopharma, Inc. Common Stock
LABP
|
+$194M |
| 2 |
BridgeBio Pharma
BBIO
|
+$68.7M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$68.4M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$62.1M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$52.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novavax
NVAX
|
+$116M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$100M |
| 3 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
+$90.4M |
| 4 |
NVTA
Invitae Corporation
NVTA
|
+$87.4M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$87.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.08% |
| 2 | Financials | 0.47% |
| 3 | Industrials | 0.2% |
| 4 | Consumer Discretionary | 0.02% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Acadia Pharmaceuticals
ACAD
$4.51B
| $36.4M | 0.46% |
+1,410,305
| New | +$62.1M |
|
|
FMTX
52
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $35M | 0.44% |
1,250,000
| – | – |
|
|
AGRX
53
DELISTED
Agile Therapeutics
AGRX
| $33.1M | 0.42% |
7,960
| – | – |
|
|
PRVB
54
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $29.9M | 0.38% |
2,852,058
-1,372,331
| -32% | -$19.3M |
|
|
CMPS
55
Compass Pathways
CMPS
$1.47B
| $29.4M | 0.37% |
797,404
-250,000
| -24% | -$11M |
|
56
United Therapeutics
UTHR
$26.1B
| $29.3M | 0.37% |
+175,000
| New | +$29.2M |
|
57
ADMA Biologics
ADMA
$2.02B
| $29.2M | 0.37% |
16,584,802
| – | – |
|
58
Nuvation Bio
NUVB
$2.28B
| $29M | 0.37% |
+3,041,004
| New | +$34M |
|
|
ISEE
59
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $28.3M | 0.36% |
4,585,512
+102,799
| +2% | +$624K |
|
60
Immatics
IMTX
$1.23B
| $28M | 0.35% |
2,500,000
| – | – |
|
61
Cogent Biosciences
COGT
$6.75B
| $28M | 0.35% |
3,188,750
| – | – |
|
|
ONCR
62
DELISTED
Oncorus, Inc.
ONCR
| $27.7M | 0.35% |
1,989,987
| – | – |
|
63
Arrowhead Research
ARWR
$12.2B
| $27.1M | 0.34% |
409,341
-661,473
| -62% | -$51.3M |
|
64
Stoke Therapeutics
STOK
$1.85B
| $26.1M | 0.33% |
671,978
| – | – |
|
65
Alphatec Holdings
ATEC
$1.48B
| $25.5M | 0.32% |
+1,800,180
| New | +$28.3M |
|
66
PMV Pharmaceuticals
PMVP
$56.5M
| $24.6M | 0.31% |
746,557
-138,999
| -16% | -$5.48M |
|
|
VRNA
67
DELISTED
Verona Pharma
VRNA
| $24.2M | 0.31% |
2,888,889
| – | – |
|
|
RNAM
68
DELISTED
Avidity Biosciences
RNAM
| $24M | 0.3% |
1,099,028
-136,790
| -11% | -$3.35M |
|
69
Health Catalyst
HCAT
$160M
| $23.7M | 0.3% |
506,084
+230,000
| +83% | +$11.1M |
|
70
Forte Biosciences
FBRX
$1.57B
| $23.5M | 0.3% |
27,400
+13,400
| +96% | +$11M |
|
71
Collegium Pharmaceutical
COLL
$1.17B
| $23.2M | 0.29% |
978,277
-1,079,791
| -52% | -$25.7M |
|
|
FUSN
72
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $20.9M | 0.26% |
1,950,167
-285,816
| -13% | -$3.34M |
|
|
DRNA
73
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $20.5M | 0.26% |
800,000
| – | – |
|
|
ONEM
74
DELISTED
1Life Healthcare
ONEM
| $20.3M | 0.26% |
519,844
| – | – |
|
|
MREO
75
Mereo BioPharma
MREO
$49.8M
| $20.2M | 0.26% |
+6,000,000
| New | +$21.2M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Perceptive Advisors held 174 positions worth $7.91B, down 15% from $9.32B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Perceptive Advisors withdrew a net $1B in Q1 2021, closing 35 positions and reducing 37 holdings. Its most notable exit was Novavax, an estimated $116M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.
Against the trend, Perceptive Advisors opened a new position in Landos Biopharma, Inc. Common Stock worth $141M.
- Perceptive Advisors's largest Q1 2021 buy was Landos Biopharma, Inc. Common Stock: 1,486,992 shares worth $141M.
- Perceptive Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $68.7M increase.
- Perceptive Advisors's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $100M.
- Perceptive Advisors fully exited Novavax in Q1 2021, selling an estimated $116M.
- Perceptive Advisors's ten largest holdings make up 41% of its $7.91B portfolio in Q1 2021.
- Perceptive Advisors opened 35 new positions and closed 35 in Q1 2021.
- Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $7.91B.
Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.